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 Myocarditis is a non-ischemic inflammatory process involving the heart muscle cells 
(myocytes) with variable clinical outcomes. In most cases the disease is self limiting; 
however, it may lead to acute heart failure, resulting in early death or heart transplantation1. 
Postmortem data have implicated myocarditis in sudden cardiac death of young adults at 
rates of 8.6% to 12%2. 
 
 Although bacteria, fungi and parasites cause myocarditis, viral infection is most 
common3. Among the most commonly identified infectious viral agents are the 
Coxsackieviruses Bs, members of the enterovirus genus of the picornavirus family4. 
Reports of isolation of Coxsackievirus from the heart or pericardial fluid of patients with 
acute myocarditis date back as far as 19655; with numerous reports since of the virus 
isolated from the cardiac tissue or pericardial fluid or showing the presence of viral 
antigens in diseased heart tissue6.  
 
In addition to the clear association between enteroviral infection and acute myocarditis, it 
has been shown that chronic, dilated cardiomyopathy can be a sequela of viral yocarditis7. 
And myocarditis has been identified as a cause of dilated cardiomyopathy in 9% of cases8  
 
 Dilated cardiomyopathy is characterized by increased left ventricular or biventricular 
dimensions with decreased left ventricular ejection fraction and is not caused by abnormal 
loading conditions or coronary ischemia. Myocardial contractility is severely impaired and 
labelled “systolic Failure”. Dilated cardiomyopathy is largely an irreversible form of heart 
muscle disease with an estimated prevalence of 1:2500; it is the third most common cause 
of heart failure and the most frequent cause of heart transplantation9. The annual incidence 
of dilated cardiomyopathy in Europe is 59,000 cases10. 
 
Attempts to isolate the virus from the myocardium in patients with dilated cardiomyopathy 
have so far been unrewarding. However, enteroviral RNA and antigen in myocardial tissue 
of patients with DCM has been achieved by serological and molecular biological 
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techniques such as slot-blot, in situ hybridization, and reverse transcription polymerase 
chain reaction. 
 
Evaluation of some patients suspected of suffering from cardiomyopathy has been 
facilitated by the use of endomyocardial biopsy. However, the clinical utility of routine 
biopsy is limited, particularly because no definitive pattern has been found in dilated 
cardiomyopathy. A specific etiological diagnosis is obtained by biopsy in only about 10% of 
patients with cardiomyopathy11, and a treatable disease is found even less often. 
 
Newer techniques are therefore needed to further expand the diagnostic utility of 
























Understanding the chronic changes in heart function following myocarditis relies on 
detecting the compositional changes that occur in the cardiac myocytes, as well as those in 
the extracellular matrix.  
In the heart, an intricate lattice of collagen-containing extracellular matrix (ECM) surrounds 
individual myocytes and myofibril bundles, ensuring correct tissue geometry and aiding 
efficient vectoral transmission of force. The extracellular matrix is a complex mixture of 
collagen fibrils, elastin, cells including fibroblasts12 and macrophages, macromolecules 
such as glycoproteins, and glycosaminoglycans together with other molecules such as 
growth factors, cytokines, and extracellular proteases. 
The concept that the extracellular matrix is inert has evidently been overturned. Excessive 
collagen, the main extracellular matrix protein, clearly is detrimental to cardiac function13. 
Collagen deposition can be controlled by hormones such as angiotensin II and 
aldosterone14. Chronic activation of the renin-angiotensin system is associated with the 
appearance of inflammatory cells and fibroblasts in the perivascular space preceding the 
changes to the vasculature that lead to perivascular fibrosis15. 
Maladaptive remodeling of the cardiac ECM is observed in various disease states16 and 
may contribute to systolic dysfunction through alterations in the tensile properties of the 
myocardium and in myocyte orientation17. 
 
However, apparent contradictions exist regarding the collagen content of the myocardium 
in disease states. Whereas collagen loss and fragmentation in heart failure have been 
observed in some studies, myocardial fibrosis has been noted in others18,19,20,21. Fibrosis is 
then believed to increase ventricular stiffness and reduce compliance and further impair 
myocardial mechanical function.  
 
Myocardium of susceptible CVB3-infected mice typically shows fibrosis, which is 




II.1. Available methods:  
 
 Traditional techniques used for the detection of changes in cardiac extracellular 
matrix include trichrome staining, Western blot analysis, immunohistochemistry, Northern 
analysis, tissue 4-hydroxyproline concentration, and scanning electron microscopy.  
 
Of the techniques just mentioned, only immunohistochemistry and scanning electron 


























III. Objectives of the current work 
 To the best of our knowledge, no study has used infra-red spectromicroscopy to 
detect the changes encountered in the myocardium of Coxsackievirus-induced myocarditis 
in mouse models.  
The present study hypothesized that infra-red spectromicroscopy can detect potentially 
important changes in murine myocarditis. The primary purpose was to determine whether 
infection of the myocardium with Coxsackievirus B3 leads to spectroscopical changes 
detectable by infra-red spectromicroscopy and to detect the properties of the cardiac 
extracellular matrix change during the transition from viral myocarditis to overt 
cardiomyopathy.  
Mice were infected with Coxsackievirus B3 (CVB3) and Fourier transform infrared imaging 
(FTIRI) was used to examine two Coxsackievirus B3-induced mouse models of 
myocarditis: C57BL/6 and ABY/SnJ, which have been shown in previous studies to reflect 
the acute and chronic forms of the disease, respectively. The protein (especially collagen) 
and lipid content of heart tissue were examined at various time points after infection in 
















IV. Myocarditis and inflammatory cardiomyopathy in humans 
 
IV.1. Aetiologies of myocarditis 
 
 Acute or chronic inflammatory process affecting the myocardium (myocarditis) can 
be caused by a wide variety of toxins and drugs (e.g., cocaine, interleukin 2) or infectious 
agents, most commonly viral (e.g. coxsackievirus, adenovirus, parvovirus, HIV), bacterial 
(e.g., diphtheria, meningococcus, psittacosis, streptococcus), rickettsial (typhus, Rocky 
Mountain spotted fever), fungal (e.g., aspergillosis, candidiasis), as well as Wipple disease 
(intestinal lipodystrophy), giant cell myocarditis, and hypersensitivity reactions to drugs 
such as antibiotics, sulphonamides anticonvulsants, and antiinflammatories. Viral 
myocarditis in utero (mumps) causes endocardial fibroelastosis (dilated cardiomyopathy in 
infants and children9). 
 
The RNA core coxsackievirus has been identified as the most frequent viral agent 
responsible for myocardial inflammation24. A causal relationship between symptomatic 
presentation and rising serum Coxsackie B viral titres has been suggested25. In addition, 
nested polymerase chain reaction (PCR) analyses of adult and paediatric myocardium 
have also demonstrated the presence of adenoviral genome in patients with idiopathic left 
ventricular dysfunction. 
 
 Age-related and regional differences seem to play a relevant role in the viral 
aetiology of myocarditis.  
Hepatitis C has been identified more frequently in Japanese patients, whereas parvovirus 
B19 genome is more commonly identified in German patients26,27. Hepatitis C virus 
antibodies and RNA have been identified in sera and cardiac tissues in patients with 
biopsy-proven myocarditis27,28,29. 
Human immunodeficiency virus (HIV) is associated with cardiotrophic viral infection 
resulting in myocarditis. Histological myocarditis was detected in 52% of cases with 
advanced HIV disease and global left ventricular dysfunction30 and in 67% of HIV infected 
cases in a post-mortem analysis31. HIV-related myocarditis has a significantly poor 
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prognosis and has been identified as the strongest predictor of death among a large 
cardiomyopathy population32. A prospective study of asymptomatic HIV-infected patients 
revealed a mean incidence of progression to dilated cardiomyopathy of 15.9% per 1000 
patients33, with the incidence being higher with CD4+ counts < 400 cells/mm3. Evidence of 
myocarditis was detected in 83% of these high-risk patients. In situ hybridization identified 
HIV-related myocarditis in 76% of this population. Whether the virus itself, medications 
used for its treatment, or myocardial coinfection is responsible for the left ventricular 
impairment remains unclear. 
 
 Therefore, the contemporary molecular techniques have substantiated the 
perception that viral infection plays a dominant role in the development of active 
myocarditis. Viral myocarditis remains the prototype for the study of the disease and its 
evolution.  




IV.2. Coxsackieviral myocarditis 
 
 Coxsackievirus is an enterovirus, a member of the picornavirus family. Enteroviruses 
constitute a major subgroup of small RNA viruses that readily infect the gastrointestinal 
tract epithelial and lymphoid tissue. They include the polioviruses, coxsackieviruses, 
echoviruses, and the more recently discovered agents that are simply designated 
enteroviruses. These are extremely small (22-30 nm in diameter), naked virions with 
eicosahydral symmetry. Enteroviruses possess single-stranded, positive-sense RNA and a 
capsid formed from 60 copies of non-glycosylated proteins (VP1, VP2, VP3, and VP4). 
Replication and assembly occur exclusively in the cellular cytoplasm; one infectious cycle 
can occur within 6 to 7 hours. This results in cessation of host cell protein synthesis and 
cell lysis with the release of new infectious progeny.  
Enteroviruses are quite resistant to acid pH (as low as 3.0). This feature helps ensure their 
safe passage through the stomach to the intestines. They are resistant to many common 
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disinfectants such as 70% alcohol, substituted phenolics, and ether. Chemical agents, such 
as 0.3% formaldehyde or free residual chloride at 0.3 to 0.4%, are effective; however, if 
sufficient extraneous organic debris is present, the virus can be protected and survive over 
longer periods. Most enteroviruses can be isolated in primates (human or simian) cell 
cultures and show characteristic cytoplasmic effects.  
 
 Coxsackievirus A serotypes, in particular, are more readily detected by inoculation of 
newborn mice. In fact, the newborn mouse is one basis for originally classifying group A 
and B coxsackieviruses.  Coxsackieviruses are widely distributed in the world. Humans 
are the main natural host. Direct or indirect faecal-oral transmission is considered the most 
common mode of spread. After infection, the virus persists in the oropharynx for 1 to 4 
weeks, and can be shed in the faeces for 1 to 18 weeks. Incubation period varies, but 
relatively short intervals (2 to 10 days) are frequent. 
 
Coxsackievirus group B (subgroup 2, 3, 4, 5) are the enteroviruses most commonly 
implicated in the acute inflammation of heart muscle (myocarditis) or its covering 
membranes (pericarditis). The consequences of infection with these agents are highly 






Derived largely from animal models, three essential pathways have been described34. 
Direct myocardial invasion by cardiotrophic virus or other infectious agents rapidly 
progresses to a second phase of immunologic activation. In the last phase, CD4+ 
activation prompts clonal expansion of B cells, resulting in further myocytolysis, additional 
local inflammation, and the production of anti-heart antibodies. 
All three mechanisms may interact within the same host; the predominant pathologic 




Following entry through the respiratory or gastrointestinal tract, the virus soon replicates, 
escapes the port of entry immunological response and is transported to the blood stream 
causing a systemic viraemia on days 0 to 3. Cytokine release activates the cardiac immune 
process. Two receptors, the Coxsackie-adenovirus receptor (CAR) and decay-accelerating 
factor (DAF), have been identified that play an important role in the attachment of the virus 
to the cardiac cell and initiation of infectious cycle in the myocytes36. Once in the cell, the 
myocyte translational apparatus translates the viral RNA as a monocistronic polyprotein 
that is subsequently cleaved into the individual viral polyproteins by the viral proteases. 
Viral RNA is replicated through a negative-strand RNA intermediate that serves as a 
template for positive-strand replicates which are encapsidized into new virions. The acute 
infectious cycle is usually completed by myocytolysis. Viral genomic persistence via 
incorporated double-stranded DNA may also contribute to myocyte dysfunction by cleaving 
dystrophin or eukaryotic initiation of Factor-4. In the following few days (2 to 7 days) 
dendritic cells and macrophages within the myocyte ingest the viral agents and there is a 
generalised immune response associated with a histological inflammatory infiltrate, with the 
subsequent expression of proinflammatory cytokines, particularly interleukin-1, interleukin-
6, TNF37,29. TNF activates endothelial cells, recruits additional inflammatory cells, and has 
direct negative inotropic effects3. 
Cytokines also activate inducible NO synthase (NOS) in cardiac myocytes. The role of NO 
in the development and progression of myocarditis is complex. NO can inhibit viral 
replication by targeting specific viral proteases, and peroxynitrate formation has potent 
antiviral effects. NOS-deficient mice have greater viral titres, a higher viral load, and more 
widespread myocyte necrosis38. On the other hand, in experimental myosin-induced 
autoimmune myocarditis, NOS expression in myocytes and macrophages is associated 
with more inflammation, whereas NOS inhibitors have been shown to reduce myocarditis 
severity38. 
Cell-mediated immunity also plays an important role in viral clearance. Cytotoxic (CD8+) 
cells recognize viral protein fragments that are presented by major histocompatibility-
complex class I antigens on the myocyte surface39  
Finally, circulating autoantibodies directed against contractile, structural, and mitochondrial 
proteins have been described in both murine and human myocarditis. One or more 
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autoantibodies have been observed in 25% to 73% of patients with biopsy-proven 
disease28  These autoantibodies may have direct cytopathic effects on energy metabolism, 
calcium homeostasis, and signal transduction. They can also induce complement activation 
with lysis of antibody-coated cells40. Removal of circulating autoantibodies by 
immunoadsorption has been shown to improve cardiac function and decrease myocardial 
inflammation41. 
In the following week and beyond, there may be a transition to idiopathic dilated 
cardiomyopathy, the mechanism of which has been only partially clarified by molecular 
techniques. Detection of viral RNA at early, intermediate, and late stages of myocardial 
infection has been demonstrated in murine models of viral myocarditis42. 
 
 The presence of low levels of ongoing viral replication may result in progressive 
myocardial damage, including apoptotic cell death, as a result of the immunologic response 
to infection37. Persistence of viral particles has also been demonstrated in patients with 
dilated cardiomyopathy43,6. When matched with an activated immune system, viral 
persistence, even without replication, has been shown to induce dilated cardiomyopathy43. 
Furthermore, cytokines have been shown to remain elevated beyond 80 days 128. 
 
 Ultimately, acute and chronic myocardial damage may lead to coronary 
microvascular spasm, resulting in myocyte necrosis, fibrosis, calcification and cardiac 
dilatation44. Endothelial cell dysfunction and distortion of nitric oxide production can 
contribute to microvascular spasm44,45. 
 
 
IV.4. Changes in extracellular matrix 
 
 The relevant role of fibrosis in the development of organ pathology is increasingly 
recognized. A number of different cardiac pathologies seem to be caused by a fibrotic 
process46. Within the heart, this fibrosis is thought to be partially mediated by transforming 
growth factor-α (GF-α), a potent profibrotic cytokine that stimulates the production of 
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extracellular matrix proteins (a potent stimulator of collagen-producing cardiac fibroblasts), 
as evidenced by overexpression and knockout models47,48,49,50. 
The increased presence of extracellular matrix proteins within the myocardium results in an 
alteration of ventricular properties that causes both systolic and diastolic dysfunction51. 
TGF-α -associated fibrosis also results in an inhomogeneous milieu for electrical 
propagation, leading to the development of arrhythmia52. Similarly, excessive production of 
extracellular proteins within the heart valves results in leaflet thickening and impaired 
motion with associated valvular dysfunction53. 
 
 In patients with dilated cardiomyopathy, collagen type I and III, as well as the 
collagen type I/type III ratio, were all shown to be elevated54. 
Sanderson et al. noted that the plasma levels of TGF-α were twice as high in patients who 
had developed idiopathic dilated cardiomyopathy when compared to controls55.  
Levels of TGF-α were also increased in macrophages present within the myocardial tissue 
of the dilated heart. In addition, genetic studies have also hinted at the possible 
involvement of TGF-alpha in dilated cardiomyopathy56,57. 
 
 
IV.5. Clinicopathological events after infection with coxsackievirus in humans 
 
 Manifestations of myocarditis range from asymptomatic ECG abnormalities to 
cardiogenic shock58. Patients may report a viral prodrome of fever, myalgia, respiratory 
symptoms, or gastroenteritis followed by an abrupt onset of haemodynamic collapse59. The 
incidence of a reported infectious viral prodrome is highly variable and ranges from 10% to 
80% of patients with documented myocarditis60,3. 
Acute dilated cardiomyopathy is the most dramatic and clinically relevant presentation of 
acute lymphocytic myocarditis61.  
 The link between clinical myocarditis and acute dilated cardiomyopathy is most 
convincingly demonstrated by endomyocardial biopsy findings58. But neither symptoms nor 
clinical course of myocarditis has been shown to correlate with the histological features of 
lymphocytic infiltrates or fibrosis61. 
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 The classification by Liebeman et al. differentiated several forms of presentations62. 
These are fulminant, acute (subacute), chronic active, and chronic persistent myocarditis. 
 
Fulminant myocarditis has a distinct viral prodrome, fever, and an abrupt onset of severe 
global left ventricular dysfunction manifested by profound haemodynamic compromise 
requiring high dose vasopressor support. There is minimal left ventricular dilatation, but 
rather thickened left ventricular walls (probably as a manifestation of interstitial oedema). 
The endomyocardial biopsy shows multiple foci of inflammatory infiltrate and necrosis. Of 
note, either borderline or active lymphocytic myocarditis can produce this dramatic clinical 
presentation59. Patients die within 2 weeks or recover with complete histological and 
functional recovery of the myocardium63. 
 
 Patients with acute (subacute) myocarditis present with moderately severe 
ventricular dysfunction without evidence of preceding clinical viral illness. The left ventricle 
is mildly dilated. The endomyocardial biopsy shows active or borderline myocarditis. 
Patients undergo complete recovery with complete resolution of histological inflammation, 
or progress to dilated cardiomyopathy with viral persistence. Recovered patients have the 
same relatively poor prognosis as those with dilated cardiomyopathy45. 
 
 The onset of chronic active myocarditis is indistinct with moderate ventricular 
dysfunction. The endomyocardial biopsies at presentation and in follow-up reveal a 
combination of active myocarditis and active healing. These patients display ongoing 
inflammation and fibrosis resulting in the development of a restrictive (non-dilated) 
cardiomyopathy usually 2 to 4 years after presentation62. 
 
 Patients with chronic persistent myocarditis manifest with non-heart failure-related 
symptoms (atypical chest pain or palpitations), because of which they are submitted to 
endomyocardial biopsy. They have normal left ventricular function despite having active or 




 Myocarditis can also be masquerading as an acute coronary syndrome64,65. Elevated 
troponin levels have proven to be a more reliable predictor of myocardial damage than 
levels of CK66. 
Electrocardiographically, there are changes suggestive of myocardial ischemia66. Despite 
angiographically normal coronary anatomy, echocardiography frequently shows evidence 
of segmental or global wall motion abnormalities64. Using myocardial indium111-labeled 
antimyosin antibody and rest thallium imaging, Sarda et al. identified 35 of 45 patients 
(78%) who presented with symptoms and signs consistent with acute coronary syndrome 
as having myocarditis (biopsy verification was not undertaken in this series)65. In another 
study of 34 patients presenting with symptoms and signs consistent with acute coronary 
syndrome, 11 patients (32%) were found to have myocarditis on biopsy67. Myocarditis 
masquerading as myocardial infarction almost universally results in a full recovery of 
cardiovascular status in previously healthy adults59,64,67,65. 
 
In sum, the disparity between the pathological findings of myocarditis and the clinical 
manifestations is well recognized. Furthermore, clinical practice guidelines are lacking 
despite the well established morbidity and mortality association with the disease63,61,60. 
 
 
IV.6. Investigative Evaluation of Myocarditis 
Thus far, evaluation of myocarditis includes biopsy-based and non-biopsy-based methods. 
 
IV.6.1. Biopsy-based methods 
IV.6.1.1. Endomyocardial biopsy 
 
 Sakakibara and Konno described transvenous endomyocardial biopsy in the early 
1960s121. Over years, the equipment and technique have evolved to the point where 
satisfactory tissue samples can be easily obtained in over 90% of diagnostic attempts and 




 Using a flexible bioptome, samples from the right ventricle (and from the left 
ventricle when required) may be obtained, usually under fluoroscopic guidance, through a 
transvenous (or transarterial) approach72. 
The right internal jugular vein is the most common percutaneous access for the right 
ventricular endomyocardial biopsy in the United States. In Germany and Italy, the femoral 
vein is commonly used69. The subclavian vein may also be used occasionally. The femoral 
artery may be used as a percutaneous access for left ventricular biopsy70.  
No comparative studies exist for left versus right ventricular biopsy; however, left 
ventricular biopsy has been used in case series to define cardiomyopathic processes 
limited to the left ventricle71. 
Ideally, samples should be obtained from more than one region of the right ventricular 
septum, and sample size should be 1 to 2 mm3. Clinical considerations determine how 
many biopsy samples are to be obtained and how they are to be fixed. Usually four to five 
samples are obtained and transferred to a fixative at room temperature (10% neutral 
buffered formalin). One or more samples may be frozen for further studies. 
 
 
IV.6.1.1.a. Histopathology  
 
 The adoption of Dallas criteria has helped improve the interpretation of finding11. 
However, there remains a lack of agreement about the diagnostic usefulness of any 
proposed scheme that utilizes conventional histological findings to evaluate inflammatory 
cardiomyopathy73,74. 
However, despite the evident progress in the design and techniques, shortcomings of the 
utility of endomyocardial biopsy still exist; including: (1) small sample size, (2) 
heterogeneous distribution of tissue pathology in many cardiac diseases leading to 
inherent sample errors, (3) subjective pathological interpretation of the microscopic findings 
(a high degree of interobserver variability), and (4) unknown true-positive/false-positive and 




 A considerable sampling error is associated with the interpretation of 
endomyocardial biopsy findings. Chow et al. and Hauck et al. have demonstrated by 
biopsying postmortem hearts of patients who had died from myocarditis that, from a single 
endomyocardial biopsy, histological myocarditis could be demonstrated in only 25% of 
samples. With more than five samples, Dallas criteria could be diagnosed in approximately 
two thirds of subjects76,77. A recent MRI study using focal imaging abnormalities to guide 
endomyocardial biopsy demonstrated that the earliest myocardial inflammatory 
abnormalities were evident in the lateral wall of the left ventricle and that only these sites 
revealed myocarditis by histological examination71. 
 The high degree of interobsever variability was shown by the Myocarditis Treatment 
Trial. Of the 111 patients diagnosed with endomyocardial biopsy, only 64% had that 
diagnosis confirmed by the expert pathology panel who reviewed the histopathological 
material60. 
 In addition, viral material can exist in the myocardium (even in a replicative form) in 
patients with viral myocarditis in the absence of myocardial inflammation adequate to meet 
the Dallas criteria and may adversely affect the outcome78. In a study by Martin et al. it was 
demonstrated in 34 children with clinical presentations compatible with myocarditis that 26 
heart biopsy samples were positive for viral pathogens, and 13 of the 26 positive samples 
had no evidence of myocarditis on histopathological examination79. 
 Another drawback of conventional histopathological findings is the dissociation 
between them and response to immune modulation therapy. In the Myocarditis Treatment 
Trial, there was no difference in the 1- or 5-year survival or 28-week ejection fraction in 
patients with Dallas criteria myocarditis treated with immunosuppressive therapy or 
placebo60. 
 
 Taken together, the current histopathological criteria (Dallas criteria) are not 
sensitive enough to identify the population with viral or autoimmune-related heart 
compromise. Despite complete evaluation, including history, clinical examination, blood 
work, echocardiography, coronary angiography, and endomyocardial biopsy, no aetiology 




IV.6.1.1.b. Immunological tools 
 
 Immunohistochemistry staining of samples obtained by endomyocardial biopsy 
enables more precise characterization of infiltrating lymphocyte subtypes80. It also helps 
define and quantify upregulation of major histocompatibility (MHC) antigens. Myocyte-
specific MHC expression approach is said to have greater sensitivity than the Dallas 
criteria81.  
In a small study cohort by Herskowitz et al., the sensitivity and specificity of any MHC 
expression for detecting biopsy-proven myocarditis were 80% and 85%, respectively30. 
Surprisingly, a more recent larger cohort study of 83 patients with suspected myocarditis82 
found no correlation between MHC immunostaining and histopathological findings of active 
myocarditis by Dallas criteria. The study investigators argue that MHC expression could 
represent a chronic form of myocardial injury and may not be responsible for the patients’ 
clinical presentation. This discordance is currently unexplained because the staining 
methods and patient population appeared to be similar59. 
Despite this discordance, assessment of MHC expression has recently been used to guide 
therapy of patients with inflammatory cardiomyopathy83. 
 
 
IV.6.2. Non-biopsy-based methods: 
IV.6.2.1. Cardiac and other biomarkers: 
 
 Serum biomarkers (creatine kinase [CK], troponin I and T) are routinely measured 
when myocarditis is suspected. CK or its isoform (CK-MB) is not generally useful for 
screening because of its low predictive value. Elevated troponin levels have proven to be a 
more reliable predictor of myocardial damage than creatine kinase levels66. 
The erythrocyte sedimentation rate was shown in an early trial to have a very low 
sensitivity and specificity84. 
 Other serum biomarkers such as complement, cytokines, and anti-heart antibodies, 




IV.6.2.2. Noninvasive imaging modalities 
 
IV.6.2.2. a. Echocardiography: 
Transthoracic echocardiography is routinely performed in the initial work-up of all patients 
with suspected myocarditis, with findings that can be varied and relatively nonspecific. 
Although anatomic features (i.e. chamber dimensions, ejection fraction, wall motion 
abnormalities) can differentiate myocarditis from other forms of cardiomyopathy, ultrasound 
tissue characterization, tissue Doppler, and myocardial velocity measurements may better 
characterize tissue changes in acute myocarditis and monitor changes over time59. 
 
 
IV.6.2.2. b. Indium111-labeled monoclonal antibody fragments  
 
 Antimyosin cardiac uptake reflects the extent of myocardial necrosis. Indium111-
labeled monoclonal antibody fragments (directed against heavy chain myosin) bind to the 
cardiac myocytes that have lost the integrity of their sarcolemmal membranes and have 
exposed their intracellular myosin to the extracellular space. On the basis of 
endomyocardial biopsy, antimyosin uptake was found by Dec et al. to be highly sensitive 
(83%) but only moderately specific (53%) for detecting myocardial necrosis86. 
It has been reported that a positive antimyosin scan and a nondilated left ventricular cavity 
(left ventricular end-diastolic dimension <62 mm) was highly predictive for detecting 
myocarditis on biopsy87. 
 
 
IV.6.2.2. c. Galium67-labeled cardiac scintigraphy 
 
 This modality detects the extent of myocardial inflammation. A sensitivity of 6% and 






IV.6.2.2. d. Contrast-enhanced magnetic resonance imaging (MRI) 
 
 In addition to anatomic and morphological information, MRI can provide accurate 
tissue characterization by measuring T1 and T2 relaxation times and spin densities. 
Assessment of relaxation times provides a sensitive measure for myocyte injury, including 
oedema and cellular swelling89. New contrast MR techniques using segmental inversion 
recovery gradient-echo pulse sequences and both early and late gadolinium enhancement 


























V. Experimental models of enteroviral cardiomyopathy 
 
 Although enteroviruses such as Coxsackie B viruses have been strongly associated 
with the pathogenesis of myocarditis and the evolution of dilated cardiomyopathy, the 
limitations of the current diagnostic strategies and clinical therapies make it difficult to 
understand the mechanisms by which enteroviral infection causes cardiomyopathy. 
Fortunately, there are well characterized murine models of CVB infection that provide a 
framework for studying the general pathogenic mechanisms. 
 
 
V.1. Murine model of acute coxsackieviral myocarditis: 
 
 Virus-mediated myocytotoxicity has been demonstrated in vivo in acute viral 
infection. Coxsackievirus infection can induce a direct cytopathic effect in cultured foetal 
human91, murine92 and rat heart cells43. The direct virus-induced cytotoxicity includes the 
presence of necrotic myofibrils in the absence of an inflammatory cell infiltrate 3 days post 
infection93, extensive cardiac damage in severe combined immunodeficiency and athymic 
mice, where the unusual inflammatory cell infiltrate is genetically reduced or absent94, and 
lack of benefit of immunosuppressive therapy in several strains of inbred mice95. 
 
 
V.2. Murine model of chronic dilated cardiomyopathy caused by Coxsackievirus 
infection: 
 
 It has been shown that experimental viral myocarditis could be associated with 
persistence of inflammation progressing to myocardial fibrosis. Wilson et al. found that 
acute infection with Coxsackievirus B3 in Swiss mice was followed by marked fibrosis, 
dystrophic mineralization, and microscopic myocardial hypertrophy, which persisted for at 
least 6 months96. Cardiomyopathy evolved in the infected mice in a natural course 
resembling acute myocarditis that progresses to dilated cardiomyopathy in humans. 
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Viral persistence and its potential role in ongoing myocyte damage were demonstrated in a 
murine model of Coxsackievirus B3-induced myocarditis using in situ hybridization for the 
presence of CVB3 genomic RNA22. 
By further examining the sites where viral RNA was detected, Klingel et al.22 found that in 
the first 3 days after infection, myocytes containing CVB3 RNA were distributed randomly 
throughout the myocardium (presumable heterogeneous infection during viraemia). By day 
6, infected myocytes were adjacent to foci of inflammatory cells. The numbers of CVB3-
infected myocytes were noted from day 6 to 9. This correlated with a significant increase in 
myocardial injury. After infectious virus could no longer be isolated from the myocardium 
(from day 15 to 30 post-infection), CVB3 genomes could still be detected in myocardial 
cells. These positive cells were found primarily within foci of myocardial lesions 
characterized by fibrosis, myocardial necrosis, and mononuclear cell infiltrates. 
Interestingly, there was evidence of viral persistence in ACA/SnJ, ABY/SnJ, and SWR/J 
mice, but not in DBA/1J mice, which were capable of terminating the inflammatory process 
through elimination of the virus from the heart.  
Permissive mouse strains (e.g. A.CA/SnJ, ABY/SnJ, SWR/J) develop ongoing 
myocarditis after acute infection due to viral persistence, while resistant mouse strains (e.g. 
DBA/1J and C57Bl/6) eliminate the virus after acute infection. Viral replication in the 
myocytes with viral persistence has been shown to be restricted at the level of gnomic 
positive-strand RNA synthesis. In contrast to the acute phase of myocarditis which is 
characterized by the synthesis of viral positive-strand RNA in great excess, cells with viral 
persistence contain positive- and negative-strand RNA in approximately the same 
abundance. Consequently, viral gene expression is decreased in persistently infected cells, 










VI. Materials and Methods 
 
VI.1. Fourier transform infrared micro-spectroscopy (FTIRM) and imaging (FTIRI): 
 
 Fourier transform infrared micro-spectroscopy (FTIRM) and imaging (FTIRI) are 
techniques that combine light microscopy and infrared spectroscopy97. Light microscopy is 
used to magnify structural detail in samples, while infrared spectroscopy provides 
information on molecular chemistry. 
FTIRM was developed over 20 years ago using a conventional thermal (e.g. globar) 
infrared light source and a single-element infrared (IR) detector. 
It has been used to identify and spatially resolve the chemical makeup of many diverse 
materials, including various plant and animal tissues, minerals and other geological 
samples, polymers films and laminates, semiconductors, forensics materials, and 
pharmaceuticals98. 
 The term FTIRI is associated with the recent development of focal plane array (FPA) 
detectors on IR microscopes99,100. The FPA detector consist of an array of IR detector 
elements that enable spectra of various parts of the sample to be projected on different 
pixels and collected simultaneously, while the concurrent measurement of all frequencies is 
retained by the phase modulation of the interferometer. Using a FPA system, the speed at 
which large IR images can be collected is dramatically improved97. 
When examining the chemical makeup of biological cells and tissues with an infrared (IR) 
microscope, it is important to achieve sub-cellular spatial resolution. For both FTIRM and 
FTIRI, the spatial resolution is limited by the wavelengths of infrared (IR) light, which are 
longer than visible light wavelengths used for conventional optical microscopy. The 
diffraction-limited spatial resolution is dependent upon the wavelength of light and the 
numerical aperture (NA) of the focusing optic101. 
 
 In an FTIRI experiment, no physical apertures are used to limit the illumination area 
of the IR beam. Instead, an array of IR detector elements is used to collect the projected 
image of the unmasked IR beam on the sample. 
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An IR spectromicroscope is used, which is designed with 2 paths from the sample to the 
detector: transmission and reflection.  
In transmission mode, the IR light passes through the sample and is collected by a second 
IR objective that re-collimates the beam and sends it to the IR detector. In reflection mode, 
the IR light reflects off of the sample and passes back through the illuminating objective. In 
this configuration, approximately 40-50% of the incident IR light is blocked by a mirror that 
collects the reflected light97. 
 To preserve the original state of the tissue, thin samples (6-10 μm) are prepared by 
cryogenic sectioning with a microtome, and no embedding material should be used. The 
cut sections are then planted on an infrared-transparent material with thickness ranging 
from nanometers to a few micrometers.  
 
 
VI.2. Experimental animal models and tissue preparation 
 
 Mouse models were prepared at Tuebingen University Medical School, Germany. In 
brief, complementary (cDNA) generated Coxsackievirus B type 3 (CVB3), Nancy strain102, 
was grown and propagated in Vero cells (African green monkey kidney cells). Stock virus 
was prepared by three times freezing and thawing and further purified by sucrose gradient 
centrifugation. Nine 4 to 5 week-old inbred mice of the strains C57BL/6 and ABY/SnJ (both 
H-2b) were infected intraperitoneally (i.p.) with 1 x 105 PFU of purified CVB3.  
Animals were sacrificed at 4, 8, 28 days post-infection; non-infected animals of the two 
mouse strains were used as controls. The hearts were removed and frozen in liquid 
nitrogen. 
All animal experiments were carried out in accordance with European and German legal 
and ethical regulations. 
 
For analysis, 8 μm thick-heart tissue sections were mounted on MirrIR reflective 
microscope slides (Kevley Technologies, Chesterland, OH) and fixed for 20 minutes at  
4 °C in 2% paraformaldehyde before use, which has been shown to preserve cellular 
components for FTIR microspectroscopy. 
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For each mouse model (ABY/SnJ and C57BL/6), nine animals were studied; three were 
used as controls and six were infected with coxsackievirus B3. 
 
The reason for studying the 2 different mouse strains was the evidence of different 
responses to Coxsackie B virus infection, as mentioned above. 
 
 
VI.3. FTIR imaging data collection 
 
 Data acquisition was performed at The National Synchrotron Light Source (NSLS), 
New York. IR images were collected using a Perkin Elmer Spectrum Spotlight FTIR 
Imaging System applying the “image” mode of the instrument. For each tissue section, the 
entire area of the tissue was defined (approximately 5 mm in diameter) and an IR image 
was produced for this area using a liquid nitrogen-cooled, 16-pixel mercury cadmium 
telluride (MCT-A) array detector at a 25 μm pixel resolution. Typically, 5000 -10,000 
spectra were collected for each tissue section. In addition, two or three smaller images 
were collected from each section at higher pixel resolution (6.25 μm). For the high-
resolution images, over 100,000 spectra were collected for each tissue section. Using a 25 
μm pixel size (4 cm-1 resolution, 4 scans/pt.), a 4 mm x 4 mm area of tissue took 110 
minutes to image. Using a 6.25 μm pixel size (4 cm-1 resolution, 4 scans/pt.), imaging the 
same area of tissue would take approximately 29 h to collect. 
An absorbance spectrum was recorded for each pixel in trans-reflectance mode. 
Background spectra were collected from a clean region of the IR-reflective slide. All spectra 
were collected in the mid-infrared spectral region (4000-720 cm-1). The spectral resolution 
was 4 cm-1 and eight scans were averaged for each spectrum. A visible image of the 
sample was also collected. 
A type I collagen sample (from bovine Achilles tendon, 4 mg/ml in 0.02 M acetic acid)103 
was prepared on a MirrIR microscope slide and used for a collagen reference spectrum. 
The spectrum was recorded using “point” mode of the Spectrum Spotlight with an aperture 
of 50 μm x 50 μm, and a spectral resolution of 4 cm-1 in the mid IR spectral region (4000-
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VI.4. FTIR imaging data evaluation 
 
 Three FTIR spectral regions were used in the data evaluation (Fig. 1): (1) lipid 
content was determined by integrating the area between 3000 and 2800 cm-1 (linear 
baseline: 3000 - 2800 cm-1), which represents the C H stretching region and is dominated 
by the long hydrocarbon chains of lipids; (2) protein content was determined by integrating 
the amide I band, 1700- 600 (single-point linear baseline at 1800 cm-1), which is assigned 
to the carbonyl stretching mode of the protein amide backbone ( NH C O); (3) 
collagen content was determined through correlation analysis of the region from 1400 to 
1000 cm-1 which has a series of absorbance features unique to collagen106. 
 
 
Fig. 1: (A) Infrared spectrum from heart tissue. The lipid/protein (L/P) band ratio is derived 
from the integrated area ratio between lipid (3000–2800 cm−1) and protein (1700–
1600 cm−1). (B) Infrared spectrum of type I collagen. The second derivative of this 
spectrum was used as a reference spectrum for correlation comparison of collagen content 





Fig. 1A shows a typical IR absorption spectrum of heart muscle tissue. The IR spectrum 
can be separated into three major regions. The peaks between 3000 and 2800 cm−1 are 
assigned to C H stretching modes. Specifically, the asymmetric C H stretching 
vibrations of the CH3 and CH2 fall at 2959 and 2921 cm−1, respectively, while the 
symmetric modes occur at 2872 and 2852 cm−1, respectively107. This region is a 
sensitive indicator for lipid content. The absorbance peak centred near 1650 cm−1 
originates from C O stretching vibration of the amide bond backbone in proteins107. The 
exact frequency of this mode depends on the secondary structure of the protein being 
examined. This peak was used to estimate the concentration of protein in tissue.  
Collagen content was determined by examining the fingerprint region from 1400 to 1000 
cm−1. The spectrum of collagen can be seen in Figure 1B. Collagen absorption features at 
1338, 1283, 1240, 1204, 1082 and 1032 cm−1 are attributed to CH2 wagging, CH3 
deformation, C N stretching and C OH stretching of collagen106,108. 
 
The correlation analysis was performed against the reference spectrum of pure type I 
collagen using the second derivative. 
 
Accordingly, two parameters were established to evaluate the FTIR images in this study: 
the lipid/protein (L/P) ratio and the collagen content. 
Images were plotted with a rainbow colour scale where lowest values were blue and 
highest values were red. All images for each parameter (L/P ratio and collagen content) 
were plotted on the same scale for comparison. 
 
To overcome sampling error, many sections from the same tissues were studied. 











Figure 2 shows the lipid / protein ratio spectral images obtained from the heart tissue 
sections of the non-infected ABY/SnJ mice and those obtained from infected mice of the 
same strain at different time points post-infection (4 days, 8 days, and 28 days post 
























ABY/SnJ whole tissue: Lipid / Amide I
A = 25µm 
 
 
Fig. 2: Lipid / protein ratio images of heart tissue from the ABY/SnJ mouse at different 
disease stages: control, 4 days, 8 days, and 28 days post-infection (25µm aperture) 
 
 
Table 1 shows the analysis of the lipid / protein ratio spectra obtained from the heart tissue 
sections of the non-infected ABY/SnJ mice and those obtained from the heart tissue 
sections of the non-infected ABY/SnJ mice and those obtained from infected mice of the 
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same strain at different time points post-infection (4 days, 8 days, and 28 days post-
infection). The aperture used is 25 µm. 
 
 
Table 1: Lipid / protein ratio (L/P) for the whole tissue of mouse strain ABY/SnJ as acquired 
at 25 µm aperture. (p.i.: post-infection) 
 
Mouse strain Non-infected 4 days p.i. 8 days p.i. 28 days p.i. 
ABY/SnJ 1 0.21 0.05  0.07 0.22 0.07 0.49 0.08 0.02 
ABY/SnJ 2 0.14 0.66 0.08 0.05 0.07 0.04 0.08 0.03 
ABY/SnJ 3 0.19 0.05    
Mean  SD 0.18 0.021 0.075 0.0050 0.070 0.000 0.080 0.000 
 
 
Data are presented as meanSD unless otherwise indicated. An error probability of P<.05 
was regarded as significant. Groups were compared using the Kruskal-Wallis ANOVA on 
ranks, and P was shown to be 0.022. 
 
Figure 3 shows the lipid / protein ratio spectral images obtained from the heart tissue 
sections of the non-infected C57BL/6 mice and those obtained from infected mice of the 
same strain at different time points post infection (4, 8, and 28 days post infection). The 







































C57 4d: 0.900±0.010 C57 8d: 0.120±0.040 C57 28d: 0.190±0.030
C57 neg: 0.090±0.0058
C57BL/6 whole tissue: Lipid / Amide I
A = 25µm 
 
Fig. 3: Lipid / protein ratio images from the C57BL/6 (25 µm aperture) mouse at different 
disease stages: control, 4 days, 8 days, and 28 days post infection 
 
Table 2 shows the analysis of the L / P ratio spectra obtained from the heart tissue sections 
of the non-infected C57BL/6 mice and those obtained from infected mice of the same strain 
at different time points post infection (4, 8, and 28 days post infection). The aperture used 
is 25 µm 
 
Table 2: Lipid / protein ratio (L/P) for the whole tissue of mouse strain C57BL/6 as aquired 
at 25 µm aperture. (p.i.: post-infection) 
Mouse strain Non-infected 4 days p.i. 8 days p.i. 28 days p.i. 
C57BL/6 1 0.08 0.03 0.10 1.32 0.08 0.29 0.22 8.98 
C57BL/6 2 0.10 0.03 0.08 0.30 0.16 0.22 0.16 5.99 
C57BL/6 3 0.09 0.05    
Mean  SD 0.090 0.0058 0.09 0.010 0.120 0.040 0.190 0.030 
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Data are presented as meanSD unless otherwise indicated. An error probability of P<.05 
was regarded as significant. Groups were compared using the Kruskal-Wallis ANOVA on 
ranks, and P was shown to be 0.031. 
 
Figure 4 shows the lipid / protein ratio spectral images obtained from the heart tissue 
sections of the non-infected ABY/SnJ mice and those obtained from infected mice of the 
same strain at different time points post infection (4, 8, and 28 days post infection). The 


























Fig. 4: Lipid / protein ratio images of heart tissue from the ABY/SnJ mouse at different 
disease stages: control, 4 days, 8 days, and 28 days post infection (6.25 µm aperture) 
 
Table 3 shows the analysis of the L / P ratio spectra obtained from the heart tissue sections 
of the non-infected ABY/SnJ mice and those obtained from infected mice of the same 
 30 
 
strain at different time points post infection (4, 8, and 28 days post infection). The aperture 
used is 6.25 µm. 
 
Table 3: Lipid / protein ratio (L/P) for the whole tissue of mouse strain ABY/SnJ as aquired 
at 6.25 µm aperture. (p.i.: post infection) 
 
Mouse strain Non-infected 4 days p.i. 8 days p.i. 28 days p.i. 
ABY/SnJ 1 0.21 0.012 0.057 0.0055 0.077 0.0092 0.061 0.0052 
ABY/SnJ 2 0.16 0.018 0.077 0.0088 0.078 0.009 0.063 0.0049 
ABY/SnJ 3 0.21 0.012    
Mean  SD 0.193 0.017 0.067 0.010 0.078 0.001 0.062 0.001 
 
Data are presented as meanSD unless otherwise indicated. An error probability of P<.05 
was regarded as significant. Groups were compared using the Kruskal-Wallis ANOVA on 
ranks, and P was shown to be 0.026. 
 
 
Figure 5 shows the lipid / protein ratio spectral images obtained from the heart tissue 
sections of the non-infected C57BL/6 mice and those obtained from infected mice of the 
same strain at different time points post infection (4, 8, and 28 days post infection). The 
aperture used is 6.25 µm. 
 
Table 4: Lipid / protein ratio (L/P) for the whole tissue of mouse strain C57BL/6 as acquired 
at 6.25 µm aperture. (p.i.: post infection) 
 
Mouse strain Non-infected 4 days p.i. 8 days p.i. 28 days p.i. 
C57BL/6 1 0.0766 0.0086 0.089 0.011 0.067 0.0078 0.159 0.018 
C57BL/6 2 0.097 0.011 0.057 0.0060 0.058 0.0064 0.294 0.0165 
C57BL/6 3 0.069 0.0076    




Data are presented as meanSD unless otherwise indicated. An error probability of P<.05 
was regarded as significant. Groups were compared using the Kruskal-Wallis ANOVA on 













BL.6 neg: 0.078±0.010 BL.6 4d: 0.087±0.032
BL.6 8d: 0.062±0.005 BL.6 28d: 0.211±0.053



















Fig. 5: Lipid / protein ratio images of heart tissue from the C57BL/6 mouse at different 
disease stages: control, 4 days, 8 days, and 28 days post infection (6.25 µm aperture) 
 
 
Table 4 shows the analysis of the lipid / protein ratio obtained from the heart tissue 
sections of the non-infected C57BL/6 mice and those obtained from infected mice of the 
same strain at different time points post infection (4, 8, and 28 days post infection). The 
aperture used is 6.25 µm. 
 
Figure 6 shows the collagen correlation images obtained from heart tissue sections of the 
non-infected ABY/SnJ mice and those obtained from infected mice of the strain at different 


























ABY/SnJ whole tissue: Collagen Correlation
A = 25µm 
 
Fig. 6: Collagen correlation images of heart tissue from the ABY/SnJ mouse at different 
disease stages: control, 4 days, 8 days, and 28 days post infection (25 µm aperture) 
 
Table 5 shows the analysis of collagen correlation (CC) obtained from heart tissue sections 
of the non-infected ABY/SnJ mice and those obtained from infected mice of the strain at 
different time points post infection (4, 8, and 28 days post infection). The aperture used is 
25 µm. 
 
Table 5: Collagen correlation (CC) for the whole tissue of mouse strain ABY/SnJ as 
acquired at 6.25 µm aperture. (p.i.: post infection) 
Mouse strain Non-infected 4 days p.i. 8 days p.i. 28 days p.i. 
ABY/SnJ 1 0.30±0.08  0.39±0.08 0.40±0.07 0.40±0.05 
ABY/SnJ 2 0.35±0.08 0.41±0.08 0.41±0.07 0.43±0.06 
ABY/SnJ 3 0.35±0.07    
Mean  SD 0.33 0.017 0.40 0.010 0.40 0.0050 0.415 0.015 
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Data are presented as meanSD unless otherwise indicated. An error probability of P<.05 
was regarded as significant. Groups were compared using the Kruskal-Wallis ANOVA on 
ranks, and P was shown to be 0.001. 
 
Figure 7 shows the collagen correlation images obtained from heart tissue sections of the 
non-infected C57BL/6 mice and those obtained from infected mice of the strain at different 




















C57/BL  neg: 0.37±0.0058
C57/BL6  4d: 0.38±0.040 C57/BL6  8d: 0.385±0.0050
C57/BL6 28d: 0.285±0.0050
C57/BL6 whole tissue: Collagen Correlation
A = 25µm
 
Fig. 7: Collagen correlation images of heart tissue from the C57BL/6 mouse at different 
disease stages: control, 4 days, 8 days, and 28 days post-infection (25 µm aperture) 
 
Table 6 shows the analysis of collagen correlation (CC) spectra obtained from heart tissue 
sections of the non-infected C57BL/6 mice and those obtained from infected mice of the 
strain at different time points post infection (4, 8, and 28 days post infection). The aperture 




Table 6: Collagen correlation (CC) for the whole tissue of mouse strain C57BL/6 as 
acquired at 25 µm aperture. (p.i.: post infection) 
 
Mouse strain Non-infected 4 days p.i. 8 days p.i. 28 days p.i. 
C57BL/6 1 0.37±0.06 0.42±0.14 0.39±0.06 0.29±0.12 
C57BL/6 2 0.37±0.06 0.34±0.12 0.38±0.06 0.28±0.11 
C57BL/6 3 0.38±0.07    
Mean  SEM 0.37 0.0058 0.38 0.040 0.385 0.0050 0.285 0.0050 
 
Data are presented as meanSD unless otherwise indicated. An error probability of P<.05 
was regarded as significant. Groups were compared using the Kruskal-Wallis ANOVA on 
ranks, and P was shown to be 0.031 
 
Figure 8 shows the collagen correlation images obtained from heart tissue sections of the 
non-infected ABY/SnJ mice and those obtained from infected mice of the same strain at 



































Aby 8d: 0.327±0.000Aby 4d: 0.415±0.005
Aby neg: 0.327±0.019
Aby 28d: 0.410±0.000
ABY/SnJ selected area: collagen correlation
A = 6.25µm
 
Fig. 8: Collagen correlation images of heart tissue from the ABY/SnJ mouse at different 
disease stages: control, 4 days, 8 days, and 28 days post infection (6.25 µm aperture) 
 
Table 7 shows the numerical analysis of collagen correlation images obtained from heart 
tissue sections of the non-infected ABY/SnJ mice and those obtained from infected mice of 
the same strain at different time points (4, 8, and 28 days post infection). The aperture 
used is 6.25 µm. 
 
Table 7: Collagen correlation (CC) for the whole tissue of mouse strain ABY/SnJ as 
acquired at 6.25 µm aperture. (p.i.: post infection) 
 
Mouse strain Non-infected 4 days p.i. 8 days p.i. 28 days p.i. 
ABY/SnJ 1 0.295±0.0976 0.4046±0.0551 0.4395±0.0592 0.4168±0.0424 
ABY/SnJ 2 0.342±0.07237 0.4267±0.0573 0.4336±0.06804 0.4135±0.0483 
ABY/SnJ 3 0.3501±0.08023    




Data are presented as meanSD unless otherwise indicated. An error probability of P<.05 
was regarded as significant. Groups were compared using the Kruskal-Wallis ANOVA on 
ranks, and P was shown to be 0.002. 
 
Table 8 shows the numerical analysis of collagen correlation images obtained from heart 
tissue sections of the non-infected C57BL/6 mice and those obtained from infected mice of 
the same strain at different time points (4, 8, and 28 days post infection). The aperture 
used is 6.25 µm. 
 
Table 8: Collagen correlation (CC) for the whole tissue of mouse strain C57BL/6 as 
acquired at 6.25 µm aperture. (p.i.: post infection) 
 
Mouse strain Non-infected 4 days p.i. 8 days p.i. 28 days p.i. 













C57BL/6 3 0.4084±0.0348 
0.3684±0.0654 
   
Mean  SD 0.3797±0.0056 0.4005±0.0102 0.3922±0.0057 0.2935±0.0802 
 
Data are presented as meanSD unless otherwise indicated. An error probability of P<.05 
was regarded as significant. Groups were compared using the Kruskal-Wallis ANOVA on 









Enteroviruses have been shown to induce an acute inflammation of the myocardium with or 
without cardiac dysfunction (myocarditis / inflammatory cardiomyopathy) that can transform 
to virus-negative cardiomyopathy. The three phases generally involved in this disease are: 
early, acute, and chronic stages. Extracellular matrix remodeling plays a significant role in 
cardiac dysfunction. Lipid replacement by collagen deposition has been recognized as one 
of major indicators in the progression of cardiac dysfunction104,105, and infrared imaging can 
be used to detect both collagen and lipid in the disease103. 
 
By analysing the lipid / protein ratio and collagen correlation data obtained throughout the 
progression of the disease in every mouse strain and comparing these with the 
composition of the heart tissue section in the non-infected state, it becomes apparent that 
the extracellular matrix plays a significant role in the transform to the chronic 
cardiomyopathy.  
The changes in the extracellular matrix are reliably depicted by infra-red 
spectromicroscopy.  
 
Figure 9 shows FTIR images for the permissive mouse strain (ABY/SnJ) at different 
disease stages: early (4th day post-infection), acute (8th day post-infection) and chronic 
(28th day post-infection). The collagen distribution can be seen in Figure 9A, as 
determined by the collagen correlation from 1400 to 1000 cm−1. All images are plotted on 
the same scale. Results show that the diseased tissue has a higher correlation with the 
pure collagen reference spectrum, indicating that collagen levels are elevated in this tissue 
compared to the control tissue. Specifically, the collagen correlation coefficients are 0.416 
± 0.011, 0.437 ± 0.003, and 0.415 ± 0.002, in the early, acute, and chronic stages, 
respectively, while in control tissue it is 0.329 ± 0.017. Both correlation maps and the 
coefficient averages indicate there is no significant difference among three disease stages 
but a 26% increase was found in the collagen correlation for the diseased tissue relative to 
the control. In addition, the FTIR images show that there is a uniform distribution of 
collagen deposition in the diseased tissue; it is not a localized effect. This is supported by 






Fig. 9.(A) Collagen correlation images and (B) lipid/protein ratio images of heart tissue from 
the ABY/SnJ mouse model at different disease stages: control, 4 days, 8 days, and 28 
days post infection. The collagen correlation was calculated using the second derivative 
spectrum of Type I collagen from 1400 to 1000 cm−1. Data collection conditions: pixel 
size=25 μm, spectral resolution= 4 cm−1, scan number=8 scans/pixel. The scale bar 
represents 1.0 mm.  
Table 9: Lipid/protein ratio and collagen correlation: means ± S.E.M 
Disease stage Control 4 days 8 days 28 days 
ABY/SnJ     
CC 0.329 ± 0.017 0.0416 ± 0.011 0.437 ± 0.003 0.415 ± 0.002 
L/P 0.193 ± 0.017 0.067 ± 0.000 0.078 ± 0.001 0.062 ± 0.001 
C57BL/6     
CC 0.380 ± 0.006 0.401 ± 0.010 0.392 ± 0.006 0.294 ± 0.080 
L/P 0.078 ± 0.010 0.087± 0.032 0.062 ± 0.005  0.211± 0.053 
 
The L/P ratio is seen in Figure 9B. As can be seen, a high L/P ratio exists for the control 
tissue (0.193 ± 0.017), and the L/P ratio is more than three times lower in all three stages 
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of infected tissue: 0.067 ± 0.010, 0.078 ± 0.001, and 0.062 ± 0.001 for early, acute and 
chronic stages, respectively. No significant differences were observed between the three 
diseased stages. Since these data are reported as ratios to account for any sample 
thickness variations, these results could indicate that the diseased states possess either a 
higher protein content and/or a lower lipid level. However, the increased collagen content is 
observed in the diseased stages, strongly suggesting that protein content is increasing. In 
addition, the CH2/CH3 ratio can be applied to indicate lipid content, where a higher ratio 
indicates longer-chained lipids and a higher lipid content103. 
In these studies, the infected tissue had CH2/CH3 ratios comparable as the control tissue, 
supporting the conclusion that the lower L/P ratio in the diseased states comes from 
elevated protein (i.e. collagen) and not a significant reduction in lipid content.  
For the C57BL/6 strain, the collagen distribution and L/P ratio images are shown in Figures 
10A and B, respectively, plotted on the same colour scales as in Figures 9A and B. No 
differences were observed in collagen correlation between the control (0.380 ± 0.006), 4 
days post-infection (0.401 ± 0.010), and 8 days post-infection (0.392 ± 0.006) tissue. 
Similarly, the L/P ratio did not differ significantly between the control (0.078 ± 0.010), 4 
days post-infection (0.087 ± 0.032), and 8 days post-infection (0.062 ± 0.005) tissue. 
However, a dramatic reduction in collagen content (0.294 ± 0.080) and increased L/P ratio 
(0.211 ± 0.053) were observed in the 28 days post-infection tissue.  
These results suggest that C57BL/6 strain can recover from the CVB3 infection during the 
acute phase of disease. In addition, the original (control) composition of the C57BL/6 strain 
differs from the ABY/SnJ strain; the C57BL/6 strain has a higher collagen content and a 
lower L/P ratio than the ABY/SnJ strain. These differences may influence the ability of the 






Fig.10: (A) Collagen correlation images and (B) lipid/protein band ratio maps of heart tissue 
from the C57BL/6 mouse models at different disease stages: control, 4 days, 8 days, and 
28 days post infection. The collagen correlation was calculated using the second derivative 
spectrum of type I collagen from 1400 to 1000 cm-1. Data collection conditions: pixel size = 




For both the ABY/SnJ and C57BL/6 strains, a strong inverse correlation was observed 
between the collagen content and the L/P ratio (Figure. 11). This is reflected in the 
negative slopes for the two linear relationships: -0.70 (ABY/SnJ) and -0.73 (C57BL/6), 
plotted on a scale from 0 to -1, representing the lowest to highest correlation. The linear 
regressions, r2, of the two lines were 0.82 (ABY/SnJ) and 0.64 (C57BL/6).  
 
Thus, as collagen concentration increases, the L/P ratio decreases, suggesting that 
extracellular matrix remodeling, i.e. collagen deposition, replaces normal tissue as the 




Fig. 11: Linear correlation between the lipid/protein ratio and the collagen correlation in the 
(left) ABY/SnJ and (right) C57BL/6 strains. Means and S.E.M.s were calculated using data 




These findings are consistent with numerous previous studies on CVB3 viral myocarditis 
using murine models. Specifically, ABY/SnJ(H-2b) is classified as a permissive host prone 
to sustaining chronic inflammation of myocarditis by CVB3-infection; C57BL/6(H-2b) is a 
resistant host, which usually eliminates CVB3 during acute myocarditis, preventing the  

















 Heart failure, a syndrome associated with a greatly heightened risk of death, is 
characterized by abnormalities of cardiac function with the inability of the heart to pump 
blood at an output sufficient to meet the requirements of the metabolizing tissues or the 
ability to do so only at abnormally elevated diastolic pressure or volume. Both the incidence 
and prevalence of heart failure are growing. The annual incidence of new cases of heart 
failure rises from less than 1 per 1000 patient-years among those younger than 45 years of 
age, to 10 per 1000 patient-years among those older than 65 year, to 30 per 1000 patient-
years (3%) for patients older than 85 years. Prevalence figures are also exponentially 
increasing from 0.1% before 50 to 55 year of age to almost 10% after the age of 80 years110  
 
Any condition that causes myocardial necrosis of produces chronic pressure or volume 
overload can lead to myocardial dysfunction and heart failure.  
 
 Cardiomyopathy, a disease of heart muscle, is causal for heart failure in 
approximately 7% of all congestive heart failure patients111. For descriptive rather than 
etiologic purposes, cardiomyopathies are designated as dilated, hypertrophic, or restrictive. 
 
 Dilated cardiomyopathy is characterized by thinning of the left ventricular wall and 
dilatation of the ventricles, resulting in a reduction of the ejection volume from the heart. 
This causes serious arrhythmias (inflammatory infiltrates may act as arrhythmogenic foci 
leading to sudden cardiac death in the absence of clinical heart failure) and 
thromboembolic events, explaining the substantial mortality rate of this disease. 
Histopathological investigations have shown that there is a moderate myocyte hypertrophy 
and death, along with replacement fibrosis112  Dilated cardiomyopathy is preceded in a 
significant proportion of patients with myocardial inflammation (myocarditis)34. 
 
 Myocarditis is a heterogeneous final common pathway for non ischemic 
inflammation of the myocardium of diverse aetiologies113. It is a common indication of listing 
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for cardiac transplantation114, and a significant cause of unexplained sudden cardiac death 
in young patients115. 
 
The causes of myocarditis include a broad range of viral, bacterial, and fungal infections, 
systemic and collagen vascular diseases, drugs, and toxins. The most common viral 
agents detected by myocardial genome PCR in biopsy-proven acute myocarditis comprise 
the enteroviruses of the family Picornaviridae, in particular Coxsackie B viruses, which 
have been established as highly prevalent human pathogens. 
 
The gold standard for the detection of myocardial inflammation (myocarditis) remains direct 
visualization of affected myocardium by either endomyocardial biopsy or autopsy. The 
diagnosis of myocarditis is based on the presence of inflammatory cells in the heart and 
can be classified by the Dallas or Marburg criteria116,117,118,119. These criteria define active or 
definitive myocarditis by the amount of inflammatory infiltrate in the myocardium, whereas 
cases with fibrosis accompanied by lesser degrees of inflammation are considered chronic, 
borderline, persistent (ongoing), and healing (resolving) myocarditis.  
Endomyocardial biopsy specimens are considered diagnostic of myocarditis if light 
microscopy reveals evidence of both infiltrating lymphocytes and myocytolysis59. 
 
Owing to its often insidious onset and highly variable clinical presentation, the real 
incidence and prevalence of histologic myocarditis is unknown. Myocarditis is detected in 
1-9% of routine postmortem examinations120. 
 
Prognosis of biopsy-proven acute myocarditis relates not only to clinical manifestations at 
onset, but also to histologic classification and biomarkers113. Studies of cellular apoptotic 
pathways show that serum levels of Fas and Fas ligands are elevated in patients with 
acute myocarditis compared with those in controls, and in fatal cases, compared with 
survivors of acute mocarditis121. Patients with fulminant myocarditis progressing to 
cardiogenic shock or death have demonstrated significantly elevated levels of serum 
interleukin-10 [IL-10]122. The next highest predictor of minimal recovery of left ventricular 
ejection fraction (LVEF) at 6 and 12 months is the elevated of Fas and tumour necrosis 
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factor alpha (TNF-α)-receptor 1 expression123. Similarly, the presence of antimyosin 
autoantibodies (AMAAB) in patients with biopsy-proven myocarditis predicted failure of 
LVEF to recover, a decline in stroke volume index (SVI), and increased myocardial 
stiffness at 6 months124  
  
 Recently, persistent viral genome expression of enterovirus, adenovirus, parvovirus 
B19, and HHV-6 have been associated with progressive impairment in left ventricular 
ejection fraction; while spontaneous elimination by the host correlated with significant 
recovery of LVEF in patients with biopsy-proven viral myocarditis125. Coxsackie B3 viral 
myocardial infection in CD4 T-cell deficient major histocompatibility complex (MHC) class II 
knockout mice and IL-4 knockout mice show heavy myocardial fibrosis after severe acute 
myocarditis, which develops between day 7 and day 21 post-infection126. 
 
 The cardiac connective tissue, a major component of the extracellular matrix, has an 
important supportive role by surrounding the various types of cells found in the heart and 
binding them to each other so that the force transmission is uniform throughout the 
myocardium. The connective tissue is produced largely by fibroblastic cells and contains 
collagen as well as other important matrix proteins such as laminin. Fibroblasts are the 
most abundant cells found in the myocardium. This underscores the importance of the 
extracellular matrix. This network also helps translate signals induced by mechanical stress 
into signals promoting cell growth. Thus, the extracellular matrix participates in the 
remodeling of the myocardium that accompanies left ventricular hypertrophy and heart 
failure. Fibrillar collagen types I and III are the most abundant proteins in the interstitial 
space127, with the ratio of type I to type III of approximately 1.3:1 to 1.9:1128. Collagen fibres 
extend from the surface of the cells to the tissue skeleton as well as from cell to cell. These 
fibres act as “struts” to hold the myofibrils in position so that the pattern of conduction is 
orderly129. In physiological amounts, collagen may help to limit the degree of ventricular 
dilatation when it is increased in proportion to the degree of myocardial hypertrophy. In 
contrast, excessive collagen in disease states (e.g. ischemia) leads to decreased 
compliance and increased chamber stiffness or reduced distensibility. The clinical result is 
poor relaxation, and hence, a diastolic heart failure. However, for left ventricular dilatation 
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to occur, “myocyte slippage” is required129. This in turn means weakening of the 
extracellular matrix, thereby allowing “remodelling” with myocyte slippage and dilatation of 
the left ventricle130.  
  
 Remodeling describes the time-dependent and often insidious structural alterations, 
whereby the relationship of the ventricular cavity volume increases out of proportion to 
mass. The distorted global ventricular geometry, with the ellipsoid-shaped ventricle 
becoming more spherical, is accompanied by changes in the myocardial interstitium that 
lead to altered orientation of the myofibrils and progressive fibrosis. The result is further 
deterioration of cardiac contractile performance.  
 
During cardiac remodeling, two broad groups of alterations are encountered: alterations in 
the myocyte component, and alterations in the extracellular matrix component128. The 
myocardium undergoes progressive myocyte loss through necrosis, apoptosis, or 
autophagy. The changes in the extracellular matrix include changes in the fibrillar collagen 
synthesis and degradation, changes in the degree of collagen cross-linking, and the loss of 
collagen struts that connect the individual cardiac myocytes131.  
Markers of collagen turnover have been shown to be increased in patients with dilated 
cardiomyopathy compared with age-matched control subjects131.  
 
 Progressive left ventricular remodeling is shown to be directly related to future 
deterioration in left ventricular performance and a less favourable clinical course in patients 
with heart failure132. 
 
 The pathogenesis of myocarditis represents a classic model of cardiac injury 
followed by host immune response in the form of cardiac inflammation. The outcome is 
critically dependent on the virulence of the causative agent, the host immune system, and 
the ability of the host to effectively repair the ensuing injury35  
 
The commonest viral triggers are Coxsackie virus, adenovirus, parvovirus, and hepatitis C 
virus. Coxsackieviruses are single-stranded RNA viruses that have natural tropism for gut 
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epithelial cells, immune cells, neurons, and cardiomyocytes. All strains of Coxsackieviruses 
gain entry into the myocardium through the coxsackie-adenovius receptor134. To facilitate 
entry into cells, Coxsackievirus produces protease 2A, a cysteine endopeptidase that can 
cleave the dystrophin-sarcoglycans complex, which is responsible for the linkage of 
myocyte cytoskeleton to the extracellular matrix135. A recent study provided significant proof 
that the production of this cytoskeleton-modifying protease is sufficient to produce dilated 
cardiomyopathy136, which can be interpreted as direct remodeling effect of the virus on the 
myocardium, through cleavage of the dystrophin-sarcoglycans complex and sacrolemmal 
disruption. On the other hand, the virus can also trigger innate immunity, which helps the 
host fight against the infection; for example, through activation of signalling for survival 
(STAT3 and gp130), and systemic clearance of the virus (interferon regulator factor-3)35. 
 
This immune response can be exuberant, leading to myocardial destruction and myocyte 
loss. However, an inadequate host immune response results in cardiac remodeling, leading 
to dilated cardiomyopathy133. 
 
 Thus, monitoring the distribution and concentration of collagen during the different 
stages of Coxsackievirus B3-induced viral myocarditis in different immunocompetent 
mouse strains will contribute to the thorough understanding of disease progression.  
 
 Murine myocarditis may be conceptualized in three phases: (1) viremia and direct 
injury up to day 3 post-infection; (2) inflammatory response from day 5 to day 14 post-
infection; and (3) variable degrees of reparation and remodelling after 14 days post-
infection37. Major determinants of long-term heart failure are the degree of cardiac tissue 
loss by apoptotic or necrotic mechanisms and cardiac remodeling following these 
damages. 
Virus-induced myocytolysis occurs early in the infective period and despite viral clearance, 
ongoing inflammation may still occur, thus aggravating the disease by influencing cardiac 




Detection of changes in the extracellular matrix has been traditionally achieved by 
dichrome staining, Western blot analysis, immunohistochemistry, Northern analysis, tissue 
4-hydroxyproline concentration, and scanning electron microscopy. Despite the many 
advantages of these techniques, shortcomings in the detection of spatial distribution of 
organ collagens are well recognized23. 
 
 The current work applied infrared spectromicroscopy in order to provide an 
alternative means of analysing collagen spatial distribution in murine models of 
Coxsackievirus B3-induced myocarditis. 
 
In Fourier transform infrared spectromicroscopy, as covalent bonds vibrate, they absorb 
energy in the form of IR light. The wavelength of the light that is absorbed depends on the 
nature of the covalent bond (e.g. C=O, N-H), the type of vibration (bending, stretching, 
etc.), and the environment of the bond. The IR spectrum of a tissue sample can be 
regarded as a molecular fingerprint of the tissue. If this molecular fingerprint is modified by 
a disease process, then IR spectromicroscopy can be used to detect and monitor that 
process137. 
 
Infrared spectroscopy alone does not reveal the spatial distribution of tissue collagen. With 
IR microscopy, however, the microscope functions in much the same way as does a 
normal light microscope, except that it uses IR light instead of visible light137. The IR 
microscope acts as a beam condenser, focusing the normally broad IR beam onto a much 
narrower area of the microtomed tissue. By varying the size of aperture, tissue sections 
can be spectroscopically mapped with a spatial resolution as high as 10 x 10 µm.  
 
Using this technique, this study demonstrated that in the acute phase of mouse model of 
CVB3-induced myocarditis, collagen content increases and L/P ratio decreases in both the 
permissive (ABY/SnJ) and resistant (C57BL/6) strains of CVB3-infected mice. This effect 
has been shown to be broadly distributed within the tissue, and not occurring in a localized 
fashion. However, in the chronic stage of the disease, the above mentioned changes 
persist only in the permissive (ABY/SnJ) strain.  
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This is consistent with the postulation that Coxsackievirus infection produces two different 
immune responses in affected immunocompetent hosts that occur along with spontaneous 
elimination of the virus by the resistant host and the viral persistence in the permissive 
host, with the progression to chronic disease.  
 
The results of this study also show that the two strains have different compositions of the 
extracellular matrix in the uninfected state, which may provide an insight into the 
mechanism for the different responses. Previous studies have shown that the composition 
of extracellular matrix in the uninfected members of the same strain does not change at 
different time points.  
 
The changes in the collagen correlation and L/P ratio in the different strains reflect the shift 
towards cardiac remodeling and the development of chronic, dilated cardiomyopathy in the 
permissive strain.  
 
 The method used in this work, however, is limited by the inability to measure the 
absolute amount of each component of the extracellular matrix exactly. It is also only 
applied in vitro and on specially prepared specimens. Moreover, it is effort-, and time-
consuming. With the development of more sophisticated microscopes and easy-to-apply 
methods for data analysis and interpretation, more can be gained on the wake of 
understanding the pathogenesis of viral myocarditis. This may help in developing new 
predictive tools for the prognosis, as well in refining the therapeutic approaches that are 













 Coxsackievirus B3 (CVB3), a member of the Picornaviridae family, is the leading 
cause of viral myocarditis, of which dilated cardiomyopathy (DCM) is a major sequela. Both 
direct viral and immune-mediated mechanisms have been shown to contribute to the 
pathogenesis of acute injury and subsequent cardiac remodelling. As the disease 
progresses, changes in both the myocytes and the extracellular matrix are detected. 
  
In addition to the myocytes, fibroblasts, and vasculature, the myocardium contains also a 
gel-like extracellular matrix (ECM)50. The extracellular matrix consists of collagens, 
proteoglycans, basal laminae, fibronectin, laminin, osteopontin, and other molecules. The 
ECM provides the myocardium with the structural integrity and alignment critical for 
pressure distribution and contractility, as well as cell growth, differentiation, and survival. 
 
Most of the interstitial matrix proteins, especially collagens (predominantly types I and III) 
are synthesized by the cardiac fibroblasts. Distortion of the extracellular matrix composition 
and protein architecture has profound implications on myocardial remodelling, plays a 
relevant role in the pathogenesis of many cardiac pathologies, and was shown to be the 
case in dilated cardiomyopathy. 
The present work has sought to determine how the composition of extracellular matrix 
changes in a murine model of viral myocarditis by applying infra-red microspectroscopy. 
The primary purpose of this study was to demonstrate the compositional alterations in 
temporal relations with progression of that disease state.  
The results of this study showed increased collagen correlations in mouse strains 
susceptible to progression to overt cardiomyopathy. This correlated with the evidently 
recognized myocardial fibrosis in chronic stages of cardiomyopathy 
These data provide an indication of the importance of changes in collagen content in the 
adverse remodeling of the failing heart and, thus, raise the possibility of pharmacological 
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prevention of the degeneration of myocardial structure and function during the transition 
from acute phase of myocarditis to chronic cardiomyopathy.  
Whether these findings are unique to the murine heart and thus not relevant to the human 
heart can only be answered by appropriate studies on human myocardium. However, 
previous studies have suggested that the human heart will show responses in the 
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